Updates

New analysis of Biogen’s aducanumab shows reduction in clinical decline in Alzheimer’s disease.

MN-166 (ibudilast) will be part of the Phase III clinical trial on progressive multiple sclerosis subjects with secondary progressive MS without relapses. 

Phase 2 clinical trial shows that ibudilast is linked to a 48% slowing in the progression of brain atrophy compared to placebo for patients with progressive MS.

CHMP's assessment supports EMA's approval of non-small cell lung cancer (NSCLC) medicine, Vizimpro (dacomitinib).

The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).

After failing to show a clear benefit over chemotherapy on its own, both the FDA and EMA do not recommend Lartruvo (olaratumab) for use in combination with chemotherapy for new STS patients.

A new biosimilar, Truxima (rituximab), shows comparable results to the reference medicine, Rituxan (rituximab), and takes FDA one step further toward expanding patient access to medicines.

Positive news for patients with early-stage FAP; results from a Portuguese study show that a liver transplant or Vyndaqel may extend survivability.

Zolgensma (onasemnogene abeparvovec-xxxx) to receive priority review by FDA as a one-time treatment of type 1 spinal muscular atrophy (SMA).

In an exploratory study Ocrevus (ocrelizumab) slowed down loss of function in the upper extremities for patients with primary progressive multiple sclerosis (PPMS).